Creative Medical Technology vs Senti Biosciences
CELZ and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELZ and SNTI compare
Senti Biosciences is the larger company, worth 1.2 times as much as Creative Medical Technology ($4.9M against $4.2M).
Creative Medical Technology scores higher on the StockData Score (7 against 4 for Senti Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELZ | SNTI |
|---|---|---|
| Size and price | ||
| Market cap | $4.2M | $4.9M |
| Share price | $0.630 | $0.157 |
| Change, 1 year | −80.8% | −91.9% |
| Change, 5 years | −98.2% | −99.8% |
| Beta (5Y) | 1.56 | 1.86 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1384× | – |
| P/B | 0.6× | – |
| Growth | ||
| Revenue growth (TTM) | −50.0% | – |
| Revenue growth, 5Y average | −48.4% | – |
| Profitability | ||
| Gross margin | 66.9% | – |
| Operating margin | −256435% | – |
| Net margin | −249160% | – |
| Return on equity | −119% (better) | −466% |
| Return on invested capital | −3737% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 23.66 (better) | 0.83 |
| Altman Z-score | −8.55 (better) | −21.35 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −190% | – |
| Shareholder yield | −190% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 5.7% | 18.6% |
| Held by insiders | 15.9% | – |
| Short interest, % of float | 1.2% | – |
Go deeper
- CELZ stock overview
- CELZ income statement
- CELZ valuation and score
- SNTI stock overview
- SNTI income statement
- SNTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.